Serotonin News and Research

Latest Serotonin News and Research

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck announced that the Committee for Medicinal Products for Human Use adopted a positive opinion on the pending Marketing Authorization Application for SYCREST (asenapine) sublingual tablets. The CHMP has recommended that the European Commission grant a marketing authorization for SYCREST for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. The CHMP did not support an indication for the treatment of schizophrenia.

25 Jun 2010

AstraZeneca, Targacept commence enrollment in TC-5214 Phase 3 clinical development for MDD

AstraZeneca and Targacept, Inc., today announced the enrollment of the first patient in the Phase 3 clinical development program for TC-5214, a nicotinic channel blocker.

23 Jun 2010

TheraQuest launches new analgesic product pipeline

TheraQuest Biosciences, Inc., a clinical stage pain management company today unveiled its analgesic product pipeline. TheraQuest also announced the launch of its new corporate website at http://www.theraquestinc.com.

23 Jun 2010

PAS technique to predict how blood platelets respond to complex conditions found during heart attack

A team of bioengineers from the University of Pennsylvania Institute for Medicine and Engineering have trained a computer neural network model to accurately predict how blood platelets would respond to complex conditions found during a heart attack or stroke.

21 Jun 2010

Serotonin transporter gene appears to increase one's risk for depression, PTSD: Study

There is a great deal of interest in factors that contribute to the vulnerability to developing post-traumatic stress disorder, or PTSD. One factor that appears to contribute to the heritable vulnerability to PTSD is a variation in the gene that codes for the serotonin transporter, also known as the serotonin uptake site. Having a shorter version of the serotonin transporter gene appears to increase one's risk for depression and PTSD after exposure to extremely stressful situations.

18 Jun 2010

Study reveals increase of enzyme MAO-A in female brain during immediate postpartum period

Within the first week after giving birth, up to 70 percent of all women experience symptoms of the baby blues. While most women recover quickly, up to 13 percent of all new mothers suffer from symptoms of a clinical-level postpartum depression. Postpartum depression is defined as a major depressive episode starting within 4 weeks after delivery and is a significant public health problem. Postpartum blues represents a major risk factor for developing postpartum depression and severe postpartum blues symptoms can be viewed as a prodromal stage for postpartum depression.

17 Jun 2010

3 new genes in genetic research of suicidal behaviour

Three genes that have barely been studied to date have now provided fresh knowledge about patients with suicidal backgrounds. This is the result of a study by a team of Spanish researchers at Mount Sinai Hospital and Columbia University in the City of New York (United States), which found that several mutations are involved. This finding could help to develop future genetic tests to identify predisposition to suicide, without ignoring the importance of social and cultural factors.

16 Jun 2010

New research may help unravel cellular brain activity involved in human decisions

Crayfish make surprisingly complex, cost-benefit calculations, finds a University of Maryland study, opening the door to a new line of research that may help unravel the cellular brain activity involved in human decisions.

16 Jun 2010

Research may lead to better treatments for depression and substance abuse

In what has been hailed as a breakthrough, scientists from Columbia University Medical Center and Weill Cornell Medical College have outlined the molecular mechanism of membrane transport. The research shows how a protein transforms its shape to transport substances across the cell membrane in order to regulate transmission of the brain's messages across the synaptic gap from one neuron to another.

11 Jun 2010

Helsinn Healthcare S.A., Eisai announce signing of licensing agreement

Helsinn Healthcare S.A. and Eisai Inc. today announce the signing of a licensing agreement granting Eisai Inc. commercialization rights for a new product for potential use in the prevention of chemotherapy-induced nausea and vomiting in the United States.

9 Jun 2010

GE Healthcare highlights molecular imaging technologies to help clinicians improve patient experiences

Focusing on helping clinicians improve experiences for their patients, GE Healthcare is highlighting an innovative portfolio of molecular imaging technologies and agents at the 57th annual meeting of the Society of Nuclear Medicine, June 5-9, in Salt Lake City.

7 Jun 2010

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.

4 Jun 2010

More insight into key receptor that influences effectiveness of serotonin-related antidepressants

University of Michigan scientists have provided the most detailed picture yet of a key receptor in the brain that influences the effectiveness of serotonin-related antidepressants, such as Prozac.

1 Jun 2010

New study finds usage of antidepressants increases risk of miscarriage in pregnant women

A new study in CMAJ (Canadian Medical Association Journal) found a 68% increase in the overall risk of miscarriage in pregnant women using antidepressants.

1 Jun 2010

Researchers identify body's natural self-repair mechanism that kicks in after spinal-cord injury

Researchers in the University of Alberta's Faculty of Rehabilitation Medicine have made an important discovery that could lead to more effective treatments for spinal-cord injuries. Karim Fouad and David Bennett have identified one of the body's natural self-repair mechanisms that kick in after injury.

31 May 2010

Combination therapy improves patients with depression symptoms: Study

New data presented today at the American Psychiatric Association's annual meeting suggests a benefit to combining L-methylfolate, a prescription medical food called Deplin, with an antidepressant at the start of treatment. This retrospective analysis showed a significantly greater improvement in depression symptoms in a shorter period of time, when patients with Major Depressive Disorder were started on combination therapy.

25 May 2010

Filing of Clinical Data's NDA for vilazodone accepted for FDA review

Clinical Data, Inc., today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for vilazodone for the treatment of major depressive disorder.

24 May 2010

Study confirms low levels of serotonin transporter in cerebral cortex of chronic ecstasy users

Levels of the serotonin transporter are low in the brains of users of ecstasy, according to a US National Institute of Drug Abuse-funded study by Toronto's Centre for Addiction and Mental Health (CAMH) and The Hospital for Sick Children (SickKids) published today in the journal Brain.

19 May 2010

Combining medicine switch with cognitive behavioral therapy can reduce symptoms of depression: Study

More than one-third of teenagers with treatment-resistant depression - many of whom had been depressed for more than two years - became symptom-free six months after switching their medication or combining a medicine switch with cognitive behavioral therapy during a multicenter study led by UT Southwestern Medical Center researchers.

18 May 2010

152 research and training grants awarded to researchers at 93 institutions nationwide

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 152 new national research and training grants totaling $50,717,000 in the first of two grants cycles for 2010. The grants, primarily to early career researchers, cover a broad range of investigator-initiated ideas at 93 institutions nationwide, from whether cadmium exposure increases the risk of endometrial cancer, to studies of plant and bacterial-bourne compounds, to a study on a protein called survivin that could lead to novel drugs targeting prostate cancer.

18 May 2010

Serotonin News and Research

Latest Serotonin News and Research

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

AstraZeneca, Targacept commence enrollment in TC-5214 Phase 3 clinical development for MDD

TheraQuest launches new analgesic product pipeline

PAS technique to predict how blood platelets respond to complex conditions found during heart attack

Serotonin transporter gene appears to increase one's risk for depression, PTSD: Study

Study reveals increase of enzyme MAO-A in female brain during immediate postpartum period

3 new genes in genetic research of suicidal behaviour

New research may help unravel cellular brain activity involved in human decisions

Research may lead to better treatments for depression and substance abuse

Helsinn Healthcare S.A., Eisai announce signing of licensing agreement

GE Healthcare highlights molecular imaging technologies to help clinicians improve patient experiences

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

More insight into key receptor that influences effectiveness of serotonin-related antidepressants

New study finds usage of antidepressants increases risk of miscarriage in pregnant women

Researchers identify body's natural self-repair mechanism that kicks in after spinal-cord injury

Combination therapy improves patients with depression symptoms: Study

Filing of Clinical Data's NDA for vilazodone accepted for FDA review

Study confirms low levels of serotonin transporter in cerebral cortex of chronic ecstasy users

Combining medicine switch with cognitive behavioral therapy can reduce symptoms of depression: Study

152 research and training grants awarded to researchers at 93 institutions nationwide

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Serotonin News and Research

Latest Serotonin News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in